NO20082580L - Fremgangsmate for fremstilling av reseptor og ligandisoformer - Google Patents

Fremgangsmate for fremstilling av reseptor og ligandisoformer

Info

Publication number
NO20082580L
NO20082580L NO20082580A NO20082580A NO20082580L NO 20082580 L NO20082580 L NO 20082580L NO 20082580 A NO20082580 A NO 20082580A NO 20082580 A NO20082580 A NO 20082580A NO 20082580 L NO20082580 L NO 20082580L
Authority
NO
Norway
Prior art keywords
preparation
ligand
fusions
receptor
isoform
Prior art date
Application number
NO20082580A
Other languages
English (en)
Inventor
Pei Jin
H Michael Shepard
Cornelia Gorman
Juan Zhang
Original Assignee
Receptor Biologix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Biologix Inc filed Critical Receptor Biologix Inc
Publication of NO20082580L publication Critical patent/NO20082580L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Det tilveiebringes fremgangsmåter for fremstilling av celleoverflatereseptorer (CSR) og ligandisoformer. Nærmere bestemt tilveiebringes isoformfusjoner som omfatter en forløpersekvens for sekresjon, prosessering og intracellulær transport. Nukleinsyremolekyler som koder for fusjonene uttrykkes i en vertscelle, og den kodete og delvis eller fullstendig prosesserte CSR eller ligandisoformen dannes i celledyrkingsmediet. Det resulterende polypeptid omfatter om ønskelig en epitopmerkelapp for påvisning og/eller rensing av det.
NO20082580A 2005-11-10 2008-06-09 Fremgangsmate for fremstilling av reseptor og ligandisoformer NO20082580L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73613405P 2005-11-10 2005-11-10
PCT/US2006/042680 WO2007064437A2 (en) 2005-11-10 2006-10-31 Methods for production of receptor and ligand isoforms

Publications (1)

Publication Number Publication Date
NO20082580L true NO20082580L (no) 2008-08-11

Family

ID=37734260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082580A NO20082580L (no) 2005-11-10 2008-06-09 Fremgangsmate for fremstilling av reseptor og ligandisoformer

Country Status (11)

Country Link
US (1) US20070166788A1 (no)
EP (1) EP1945662A2 (no)
JP (1) JP2009515521A (no)
KR (1) KR20080082628A (no)
CN (1) CN101384621A (no)
AU (1) AU2006320858A1 (no)
BR (1) BRPI0618449A2 (no)
CA (1) CA2628959A1 (no)
NO (1) NO20082580L (no)
RU (1) RU2008123518A (no)
WO (1) WO2007064437A2 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007036945A2 (en) 2005-09-30 2007-04-05 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
US7678769B2 (en) 2001-09-14 2010-03-16 Compugen, Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
JP2007525187A (ja) * 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
EP2281877A3 (en) 2003-05-21 2011-06-01 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
BRPI0618488A2 (pt) * 2005-11-10 2011-08-30 Receptor Biologix Inc proteìnas de fusão de ìntron de fator de crescimento de hepatócito
AT505574B1 (de) * 2007-08-10 2009-09-15 Affiris Forschungs & Entwicklungs Gmbh Mimotope zur behandlung von atherosklerose
EP2238162A1 (en) * 2008-01-24 2010-10-13 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Induced internalization of surface receptors
EP2281047B1 (en) 2008-04-15 2020-04-08 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
US8927232B2 (en) * 2008-12-11 2015-01-06 Korea Advanced Institute Of Science And Technology (Kaist) Fusion protein capable of binding VEGF-A and TNF-alpha
JP6008842B2 (ja) 2010-05-04 2016-10-19 ファイブ プライム セラピューティックス インコーポレイテッド Ｃｓｆ１ｒに結合する抗体
US9676871B2 (en) * 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
KR101963230B1 (ko) * 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
KR20140036905A (ko) * 2012-09-18 2014-03-26 삼성전자주식회사 이중특이 항체를 포함하는 단백질 복합체
CA2894511C (en) 2012-12-11 2021-12-07 Albert Einstein College Of Medicine Of Yeshiva University Methods for high throughput receptor:ligand identification
KR20170016501A (ko) 2014-06-23 2017-02-13 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
US9710451B2 (en) * 2014-06-30 2017-07-18 International Business Machines Corporation Natural-language processing based on DNA computing
SG11201702723VA (en) 2014-10-29 2017-05-30 Five Prime Therapeutics Inc Combination therapy for cancer
AU2015369854B2 (en) 2014-12-22 2021-07-01 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
EP3253779A1 (en) 2015-02-06 2017-12-13 Cargill, Incorporated Modified glucoamylase enzymes and yeast strains having enhanced bioproduct production
CA2979410A1 (en) 2015-03-27 2016-10-06 Cargill, Incorporated Glucoamylase-modified yeast strains and methods for bioproduct production
MX2017013178A (es) * 2015-04-13 2018-03-01 Five Prime Therapeutics Inc Terapia de combinacion para cancer.
US10388404B2 (en) 2015-10-27 2019-08-20 International Business Machines Corporation Using machine-learning to perform linear regression on a DNA-computing platform
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
EP3494129A1 (en) * 2016-08-05 2019-06-12 Cargill, Incorporated Leader-modified glucoamylase polypeptides and engineered yeast strains having enhanced bioproduct production
EP3558339B1 (en) 2016-12-22 2024-01-24 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
BR112020004879A2 (pt) 2017-09-13 2020-09-15 Five Prime Therapeutics, Inc. métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer
US11788068B2 (en) 2017-10-25 2023-10-17 Roche Molecular Systems, Inc. Modified/mutant bacterial luciferases
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CA3093885A1 (en) * 2018-07-25 2020-01-30 Alteogen, Inc. Novel hyaluronidase variants and pharmaceutical composition comprising the same
EP3785701A4 (en) * 2019-03-25 2022-03-16 Alteogen, Inc. PHARMACEUTICAL COMPOSITION, WITH HUMAN HYALURONIDASE PH20 VARIANT AND ACTIVE SUBSTANCE, FOR SUBCUTANEOUS INJECTION
JP7445250B2 (ja) * 2019-09-09 2024-03-07 シンフォニアテクノロジー株式会社 発現ベクター及び目的タンパク質の製造方法
KR20230009872A (ko) 2020-05-12 2023-01-17 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
CN114807145B (zh) * 2022-06-02 2024-02-20 新乡医学院 一种提高非帽子依赖翻译效率的前导序列及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
JP2002511264A (ja) * 1998-04-16 2002-04-16 ジェネンテック・インコーポレーテッド 組織プラスミノーゲン活性化因子プロ配列を使用するグリコシル化タンパク質の分泌
EP1463751B1 (en) * 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
JP2007525187A (ja) * 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
BRPI0618488A2 (pt) * 2005-11-10 2011-08-30 Receptor Biologix Inc proteìnas de fusão de ìntron de fator de crescimento de hepatócito

Also Published As

Publication number Publication date
JP2009515521A (ja) 2009-04-16
CA2628959A1 (en) 2007-06-07
CN101384621A (zh) 2009-03-11
AU2006320858A1 (en) 2007-06-07
US20070166788A1 (en) 2007-07-19
BRPI0618449A2 (pt) 2011-08-30
KR20080082628A (ko) 2008-09-11
WO2007064437A2 (en) 2007-06-07
EP1945662A2 (en) 2008-07-23
RU2008123518A (ru) 2009-12-20
WO2007064437A3 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
NO20082580L (no) Fremgangsmate for fremstilling av reseptor og ligandisoformer
SG162834A1 (en) Refolding of recombinant proteins
DK1819729T3 (da) Fremgangsmåde til fremstilling af carboxy-terminalt amiderede peptider
DK1836299T4 (da) Polypeptider, der har cellobiohydrolaseaktivitet, og polynukleotider, der koder for disse
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
ATE427156T1 (de) Poríse membran und aufzeichnungsmedium sowie herstellungsverfahren dafur
ATE512980T1 (de) Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
ATE421994T1 (de) Genexpressionsmethode
WO2003106684A3 (en) PROCESS FOR THE SIMULTANEOUS PRODUCTION OF SEVERAL PROTEINS; VECTORS AND CELLS USED IN THIS PROCESS
NO20065084L (no) Interferon-alfa polypeptider og konjugater
WO2008157350A3 (en) Methods and materials for reducing biofilms
WO2006136831A3 (en) Gene expression technique
BRPI0515748A (pt) proteìna recombinante produzida por bactérias gram-positivas, método para fabricá-la, para isolar ìons de metal de um lìquido, para converter um substrato em um produto, seu uso e respectivo kit
WO2008114673A1 (ja) ポリペプチドの製造方法
WO2009054433A1 (ja) 異種タンパク質製造のための細胞及びそれを用いた製造方法
WO2007030803A3 (en) Method for preparing trimeric proteins
ES2553329T3 (es) Huésped recombinante para la producción de L-asparaginasa II
NO20072966L (no) Polypeptider som har antimikrobeaktivitet og polynukleotider som koder for disse
PH12017502080A1 (en) Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
DE602005017034D1 (de) Signalpeptid zur herstellung eines polypeptids
EA201000945A1 (ru) Конструирование системы секреции на основе sm-белков
DK2460823T3 (da) Modificeret sekretionssystem til øget ekspression af polypeptider ibakterier
WO2010013789A1 (ja) タンパク質製造方法，融合タンパク質及び抗血清

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application